Gene Editing and CRISPR in 2026: The Technology Reshaping Human Health
GGI Insights
In December 2023, the United States Food and Drug Administration approved Casgevy, the first therapy built on CRISPR gene editing, for the treatment of sickle cell disease. A patient's own stem cells...
Table of contents
How CRISPR Works: The Molecular Scissors Explained
Casgevy and the Sickle Cell Breakthrough
Beyond Sickle Cell: CRISPR Clinical Trials in 2026